Concomitant Chemoradiotherapy as Primary Therapy for Advanced Head and Neck Cancer

Korean Journal of Head & Neck Oncology 2002;18(2):163-167.
Published online November 30, 2002.

Joo Yun Lee;Dong Wook Lee;Young Seok Choi;Hong Ryul Jin;Hyun Seok Lee;Je Yeob Yeon;See Ok Shin

진행된 두경부암에서의 항암방사선 동시요법의 치료효과

이주연;이동욱;최영석;진홍률;이현석;연제엽;신시옥

Abstract

Background: To achieve the efficacy and toxic effects of concomitant FP chemoradiotherapy regimen by means of response and survival in patients with advanced head and neck cancer. Patient and Method: Thirty-three previously untreated patients with newly diagnosed advanced head and neck cancer were retrospectively reviewed.
Results
Thirty-one patients were evaluable for the tumor response. Total response rate was 93%(complete response 60%, partial response 33%). Disease free survival was 37 month and 3-year overall survival was 63%. Grade 3 or 4 stomatitis was observed in 83% and appeared as the dose limiting toxicity for this regimen.
Conclusion
Concomitant chemoradiotherapy with cisplastin and 5-fluorouracil is effective as primary therapy for advanced head and neck cancer. The majority of patients experienced severe stomatitis. Identification of less toxic regiment and improved disease control emerge as important future research goals.

Key Words: Chemoradiotherapy, Advanced head and neck cancer